| Gene symbol | PRDX2 | Synonyms | HEL-S-2a, NKEF-B, NKEFB, PRP, PRX2, PRXII, PTX1, TDPX1, TPX1, TSA | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19p13.13 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | peroxiredoxin 2 | ||||
| GTO ID | GTC2080 |
| Trial ID | NCT03891706 |
| Disease | Solid Tumor |
| Altered gene | TSA |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | TSA TCR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | An Open, Single-center, Stage I Clinical Study of Individualized Tumor Specific TCR-T Cells in the Treatment of Advanced Solid Tumors. |
| Year | 2019 |
| Country | China |
| Company sponsor | Guangzhou FineImmune Biotechnology Co., LTD. |
| Other ID(s) | FI-FIT001-000 |
| Cohort 1 | |||||||||
|
|||||||||